Updated Dec. 20, 2021
Thrombosis with thrombocytopenia syndrome (TTS) after Johnson & Johnson’s Janssen (J&J/Janssen) COVID-19 vaccination
CDC and FDA identified 57 confirmed reports of people who got the J&J/Janssen COVID-19 vaccine and later developed TTS.
CDC has also identified nine deaths that have been caused by or were directly attributed to TTS following J&J/Janssen COVID-19 vaccination.
Women ages 30-49 years, especially, should be aware of the increased risk of this rare adverse event. There are other COVID-19 vaccine options available for which this risk has not been seen.
Guillain Barre Syndrome
GBS is a rare disorder where the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis. Most people fully recover from GBS, but some have permanent nerve damage.
There have been around 278 preliminary reports of GBS identified in VAERS as of December 8, 2021. These cases have largely been reported about 2 weeks after vaccination and mostly in men, many in those ages 50 years and older.
Based on the data, the rate of GBS within the first 21 days following J&J/Janssen COVID-19 vaccination was found to be 21 times higher than after Pfizer-BioNTech or Moderna (mRNA COVID-19 vaccines). After the first 42 days, the rate of GBS was 11 times higher following J&J/Janssen COVID-19 vaccination.